PMID: 7009759Jan 1, 1980Paper

Differential graft resistance of C3H mice pretreated with antitumor drugs against BALB/c bone marrow or lymphoma cells

Journal of Immunopharmacology
F Campanile, E Bonmassar

Abstract

Sequential treatment of mice with 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) and Cyclophosphamide (Cy) produced long-term inhibition of endogenous cells proliferation in the spleen and impairment of classical allograft response, similar to that obtainable with lethal total body irradiation. The growth of BALB/c bone marrow or of virus-induced LSTRA leukemia of BALB/c origin, was studied comparatively in drug-treated or irradiated histocompatible (BALB/c x DBA/2)F1 or allogeneic C3H/HeN hosts. No splenic resistance of Hh type against bone-marrow cells was detected in C3H recipients, either irradiated or drug-treated, confirming previous studies on the Hh susceptibility of C3H strain. In contrast, strong transplantation resistance was detected in the spleen, liver and lung of the same hosts, irradiated or drug-treated, and challenged with LSTRA cells. It follows that Hh-susceptible mice are competent for mounting a localized radioresistant and drug-resistant response, directed against a virus-induced lymphoma.

References

Jan 1, 1976·Advances in Immunology·R E Anderson, N L Warner
Jun 1, 1979·Immunopharmacology·C RiccardiE Bonmassar
Jan 1, 1978·Advances in Cancer Research·R B Herberman, H T Holden
Jan 1, 1979·Immunological Reviews·G Cudkowicz, P S Hochman
Jan 1, 1979·Immunological Reviews·R Kiessling, H Wigzell
Mar 1, 1979·Journal of the National Cancer Institute·R B Herberman, H T Holden
Jan 1, 1979·Journal of Immunopharmacology·J L Turk, D Parker
Jan 1, 1979·Immunological Reviews·R B HerbermanP Puccetti
Jul 1, 1971·The Journal of Experimental Medicine·G Cudkowicz, M Bennett
Jan 1, 1974·Advances in Cancer Research·R B Herberman
Dec 1, 1968·Journal of Pharmaceutical Sciences·T L LooB J Shepard

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.